Literature DB >> 2647314

Hepatic arterial chemotherapy for primary and metastatic liver cancers.

W Ensminger1.   

Abstract

Hepatic arterial chemotherapy represents a means of selectively exposing hepatic tumor to cytotoxic agents. Although 5-fluoro-2'-deoxyuridine has been shown to generate a higher response rate in the treatment of colorectal liver metastases than that achieved by intravenous infusion, responses are largely incomplete and rarely of long duration. This review describes the rationale for the use of the thymidine analogs 5-bromo-2'-deoxyuridine and 5-iodo-2'-deoxyuridine in hepatic arterial infusions and indicates how combination therapy adding radiotherapy, specifically with hepatic arterially administered yttrium-90 microspheres, might generate a new, more efficient and effective therapeutic approach.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2647314     DOI: 10.1007/bf00647244

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  34 in total

1.  Roentgen therapy of hepatic metastases.

Authors:  R PHILLIPS; D A KARNOFSKY; L D HAMILTON; J J NICKSON
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1954-05

2.  Primary malignant tumors of the liver.

Authors:  A A el-Domeiri; A G Huvos; H S Goldsmith; F W Foote
Journal:  Cancer       Date:  1971-01       Impact factor: 6.860

3.  The 131I antiferritin breakthrough.

Authors:  C G Moertel
Journal:  J Clin Oncol       Date:  1986-04       Impact factor: 44.544

4.  Therapy for hepatocellular cancer with intrahepatic arterial adriamycin and 5-fluorouracil combined with whole-liver irradiation: a Northern California Oncology Group Study.

Authors:  M A Friedman; P A Volberding; M J Cassidy; K J Resser; T H Wasserman; T L Phillips
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

5.  A Phase I study of intermittent intravenous bromodeoxyuridine (BUdR) with conventional fractionated irradiation.

Authors:  T J Kinsella; A Russo; J B Mitchell; J Rowland; J Jenkins; J Schwade; C E Myers; J M Collins; J Speyer; P Kornblith
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-01       Impact factor: 7.038

6.  Clinical pharmacology of 5-iodo-2'-deoxyuridine and 5-iodouracil and endogenous pyrimidine modulation.

Authors:  R W Klecker; J F Jenkins; T J Kinsella; R L Fine; J M Strong; J M Collins
Journal:  Clin Pharmacol Ther       Date:  1985-07       Impact factor: 6.875

7.  Major hepatic resection for neoplasia: personal experience in 108 patients.

Authors:  J G Fortner; D K Kim; B J Maclean; M K Barrett; S Iwatsuki; A D Turnbull; W S Howland; E J Beattie
Journal:  Ann Surg       Date:  1978-09       Impact factor: 12.969

8.  Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial.

Authors:  N Kemeny; J Daly; B Reichman; N Geller; J Botet; P Oderman
Journal:  Ann Intern Med       Date:  1987-10       Impact factor: 25.391

9.  Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study.

Authors:  S E Order; G B Stillwagon; J L Klein; P K Leichner; S S Siegelman; E K Fishman; D S Ettinger; T Haulk; K Kopher; K Finney
Journal:  J Clin Oncol       Date:  1985-12       Impact factor: 44.544

10.  A phase I study of intravenous iododeoxyuridine as a clinical radiosensitizer.

Authors:  T J Kinsella; A Russo; J B Mitchell; J M Collins; J Rowland; D Wright; E Glatstein
Journal:  Int J Radiat Oncol Biol Phys       Date:  1985-11       Impact factor: 7.038

View more
  3 in total

1.  Vortex mixing catheter.

Authors:  J R Shanebrook; K B Tillotson; B L Weick
Journal:  Med Biol Eng Comput       Date:  1992-01       Impact factor: 2.602

2.  Response of human HT-29 colorectal tumor cells to extended exposure to bromodeoxyuridine.

Authors:  J Maybaum; M S Hafner; E C Burton; P L Stetson; W D Ensminger; C E Rogers
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 3.  Chemoembolization and radioembolization for hepatocellular carcinoma.

Authors:  Riad Salem; Robert J Lewandowski
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-26       Impact factor: 11.382

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.